0001104659-24-008862.txt : 20240131 0001104659-24-008862.hdr.sgml : 20240131 20240131165601 ACCESSION NUMBER: 0001104659-24-008862 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240129 FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHWARTZ BRIAN CENTRAL INDEX KEY: 0001431322 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50626 FILM NUMBER: 24583723 MAIL ADDRESS: STREET 1: C/O ARQULE, INC. STREET 2: 1 WALL STREET, 6TH FLOOR CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001130166 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 911766850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 BUSINESS PHONE: 908-517-7330 MAIL ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 FORMER COMPANY: FORMER CONFORMED NAME: XCYTE THERAPIES INC DATE OF NAME CHANGE: 20001218 4 1 tm244773-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-29 0 0001130166 Cyclacel Pharmaceuticals, Inc. CYCC 0001431322 SCHWARTZ BRIAN C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500 BERKELEY HEIGHTS NJ 07922 1 1 0 0 Interim Chief Medical Officer 0 Common Stock 2024-01-29 4 A 0 12500 0 A 15205 D Stock Option (right to buy) 2.28 2024-01-29 4 A 0 12500 0 A 2034-01-29 Common Stock 12500 12500 D Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. /s/ Brian Schwartz 2024-01-31